毕卡拉治疗公司的首席执行官克莱尔·马祖姆达在2026年3月底出售了100万美元的股票,使她的股份减少到约339,400个. Bicara Therapeutics CEO Claire Mazumdar sold $1 million in shares in late March 2026, reducing her stake to about 339,400 shares.

比卡拉治疗公司的首席执行官克莱尔·马祖姆达在2026年3月4日至20日期间以18.73美元至19.17美元之间的价格出售了53,600股,筹集了约100万美元. Bicara Therapeutics CEO Claire Mazumdar sold 53,600 shares between March 4 and 20, 2026, at prices between $18.73 and $19.17, raising about $1 million. 公司在3月9日的最大出售额为36766股. The largest sale was on March 9, when she sold 36,766 shares. 交易后,她的股份下降到339,392股,估值约为640万美元. After the transactions, her stake dropped to 339,392 shares, valued at roughly $6.4 million. 股票在3月20日收盘时价格为18.41美元,交易量高于平均水平. The stock closed at $18.41 on March 20, with higher-than-average volume. 这家公司开发神经激素治疗精神疾病, 均有"中等购买"评级和目标价30.25美元. The company, developing neurohormone therapies for psychiatric disorders, has a consensus “Moderate Buy” rating and a target price of $30.25.